Jena, Germany
Jena, Germany
SEARCH FILTERS
Time filter
Source Type

Schmal H.,Albert Ludwigs University of Freiburg | Salzmann G.M.,Albert Ludwigs University of Freiburg | Niemeyer P.,Albert Ludwigs University of Freiburg | Langenmair E.,Albert Ludwigs University of Freiburg | And 4 more authors.
BioMed Research International | Year: 2014

Cytokine regulation possibly influences long term outcome following ankle fractures, but little is known about synovial fracture biochemistry. Eight patients with an ankle dislocation fracture were included in a prospective case series and matched with patients suffering from grade 2 osteochondritis dissecans (OCD) of the ankle. All fractures needed external fixation during which joint effusions were collected. Fluid analysis was done by ELISA measuring aggrecan, bFGF, IL-1β, IGF-1, and the complement components C3a, C5a, and C5b-9. The time periods between occurrence of fracture and collection of effusion were only significantly associated with synovial aggrecan and C5b-9 levels (P < 0.001). Furthermore, synovial expressions of both proteins correlated with each other (P < 0.001). Although IL-1β expression was relatively low, intra-articular levels correlated with C5a (P < 0.01) and serological C-reactive protein concentrations 2 days after surgery (P < 0.05). Joint effusions were initially dominated by neutrophils, but the portion of monocytes constantly increased reaching 50% at day 6 after fracture (P < 0.02). Whereas aggrecan and IL-1β concentrations were not different in fracture and OCD patients, bFGF, IGF-1, and all complement components were significantly higher concentrated in ankle joints with fractures (P < 0.01). Complement activation and inflammatory cell infiltration characterize the joint biology following acute ankle fractures. © 2014 Hagen Schmal et al.


PubMed | Inflarx Inc. and Albert Ludwigs University of Freiburg
Type: | Journal: BioMed research international | Year: 2014

Cytokine regulation possibly influences long term outcome following ankle fractures, but little is known about synovial fracture biochemistry. Eight patients with an ankle dislocation fracture were included in a prospective case series and matched with patients suffering from grade 2 osteochondritis dissecans (OCD) of the ankle. All fractures needed external fixation during which joint effusions were collected. Fluid analysis was done by ELISA measuring aggrecan, bFGF, IL-1 , IGF-1, and the complement components C3a, C5a, and C5b-9. The time periods between occurrence of fracture and collection of effusion were only significantly associated with synovial aggrecan and C5b-9 levels (P < 0.001). Furthermore, synovial expressions of both proteins correlated with each other (P < 0.001). Although IL-1 expression was relatively low, intra-articular levels correlated with C5a (P < 0.01) and serological C-reactive protein concentrations 2 days after surgery (P < 0.05). Joint effusions were initially dominated by neutrophils, but the portion of monocytes constantly increased reaching 50% at day 6 after fracture (P < 0.02). Whereas aggrecan and IL-1 concentrations were not different in fracture and OCD patients, bFGF, IGF-1, and all complement components were significantly higher concentrated in ankle joints with fractures (P < 0.01). Complement activation and inflammatory cell infiltration characterize the joint biology following acute ankle fractures.


Inflarx Inc. | Entity website

InflaRx develops new first-in-class therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. InflaRx primary focus lies on the development of monoclonal antibodies targeting activation products of the complement system for application in life threatening inflammatory diseases


Inflarx Inc. | Entity website

InflaRx develops new first-in-class therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. InflaRx primary focus lies on the development of monoclonal antibodies targeting activation products of the complement system for application in life threatening inflammatory diseases


Inflarx Inc. | Entity website

InflaRx develops new first-in-class therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. InflaRx primary focus lies on the development of monoclonal antibodies targeting activation products of the complement system for application in life threatening inflammatory diseases


Inflarx Inc. | Entity website

InflaRx develops new first-in-class therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. InflaRx primary focus lies on the development of monoclonal antibodies targeting activation products of the complement system for application in life threatening inflammatory diseases


Inflarx Inc. | Entity website

InflaRx develops new first-in-class therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. InflaRx primary focus lies on the development of monoclonal antibodies targeting activation products of the complement system for application in life threatening inflammatory diseases


Inflarx Inc. | Entity website

InflaRx develops new first-in-class therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. InflaRx primary focus lies on the development of monoclonal antibodies targeting activation products of the complement system for application in life threatening inflammatory diseases


Inflarx Inc. | Entity website

InflaRx develops new first-in-class therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. InflaRx primary focus lies on the development of monoclonal antibodies targeting activation products of the complement system for application in life threatening inflammatory diseases

Loading Inflarx Inc. collaborators
Loading Inflarx Inc. collaborators